Tildacerfont clinical trials
Also written SPR001.
- studies test it
- 4
- open now
- 0
- in phase 3
- 0
- first study started
- 2017
How each study uses tildacerfont is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
4 studies that test it; most in 2017 (1)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2018 | 1 |
| 2021 | 1 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 2
- 4
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Spruce Biosciences (4)
Studies
Open first, then newest update. How each study uses tildacerfont is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- A Phase 2 Study to Evaluate the Safety, Efficacy and PK of Tildacerfont in Children Aged 2-17 Years With CAHTerminatedPhase 2Spruce BiosciencesNCT05128942Written as Tildacerfont
- Study of SPR001 in Adults With Classic Congenital Adrenal HyperplasiaCompletedPhase 2Spruce BiosciencesNCT03257462Written as SPR001
- A Study of Safety and Efficacy of Tildacerfont in Females With Polycystic Ovary Syndrome and Elevated Adrenal AndrogensTerminatedPhase 2Spruce BiosciencesNCT05370521Written as Tildacerfont
- Study to Evaluate the Safety and Efficacy of SPR001 in Subjects With Classic Congenital Adrenal HyperplasiaCompletedPhase 2Spruce BiosciencesNCT03687242Written as SPR001
Codes
What other systems call tildacerfont · ClinicalTrials.gg INT014181
- UNII (FDA) 09QCEV5481TILDACERFONTOne source FDA
- NCI Thesaurus C171816TildacerfontOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 09QCEV5481 | TILDACERFONT | One source FDA |
| NCI Thesaurus | C171816 | Tildacerfont | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.